Otsu, Japan

Masanobu Kuroda

This inventor holds 3 USPTO granted patents. Top assignees: Takara Bio Inc., Takara Shuzo Co., Inc.. Active years: 2002-2009.


% Patents Active = 33.3

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2002-2009

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Masanobu Kuroda: Innovator in Antigenic Protein Research

Introduction

Masanobu Kuroda is a notable inventor based in Otsu, Japan. He has made significant contributions to the field of antigenic proteins derived from fungi. With a total of 3 patents, Kuroda's work focuses on developing diagnostic and therapeutic agents for allergies.

Latest Patents

Kuroda's latest patents include a substantially pure, isolated, antigenic protein from fungi of the genus Malassezia. This antigenic protein is characterized by its binding ability to IgE antibodies from patients with allergies. The invention also encompasses an antigenic fragment derived from the protein and an antibody against the antigenic protein or its fragments. The goal of this invention is to provide an isolated and purified antigenic protein with high purity, along with a specific antibody for diagnostic, therapeutic, or prophylactic applications for allergies.

Career Highlights

Throughout his career, Kuroda has worked with prominent companies such as Takara Bio Inc. and Takara Shuzo Co., Inc. His innovative research has contributed to advancements in the understanding and treatment of allergic conditions.

Collaborations

Kuroda has collaborated with notable coworkers, including Ikunoshin Kato and Tomoko Yagihara. Their combined efforts have furthered research in the field of antigenic proteins.

Conclusion

Masanobu Kuroda's contributions to the field of antigenic proteins highlight his role as an influential inventor. His work continues to pave the way for advancements in allergy diagnostics and therapeutics.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…